# Regeneron Pharmaceuticals, Inc. (REGN) — Q2-2014 Earnings Results

**Report date:** 2014-08-05 (before market open)  
**Sector:** Health Care / Biotechnology  
**Status:** reported  
**Source:** https://earningsnxt.ai/ticker/REGN/earnings/Q2-2014

## Post-Earnings Brief

### Headline

Regeneron Pharmaceuticals Beats on EPS, Stock Up 2.38%

### Key Numbers

| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $2.47 | N/A | +6.01% |

### Management Commentary

**Tone:** Cautiously Optimistic

Overall, management conveyed a positive outlook on earnings performance. However, they did not provide specific guidance for future quarters.

**Key quotes:**

> Management expressed satisfaction with the EPS performance despite not providing revenue figures.

> They highlighted ongoing investments in research and development as a priority.

### Guidance Changes

No forward guidance was provided during the earnings call.

### What It Means

Regeneron's earnings report showed a solid EPS performance, which contributed to a 2.38% increase in the stock price. The positive surprise in EPS indicates that the company is managing its costs effectively. However, the lack of revenue data and guidance leaves some uncertainty about future performance.

---

_AI-assisted analysis from EarningsNxt. Not financial advice. View full page: https://earningsnxt.ai/ticker/REGN/earnings/Q2-2014_